AbbVie | ABBV - Des Atouts





Des Atouts Changement Date
AbbVie USD 136.46B 2.5B 2026-03
Abbott USD 110.43B 23.72B 2026-03
ALKERMES USD 4.26B 1.77B 2026-03
Amgen USD 92.5B 1.92B 2026-03
AstraZeneca USD 114.02B 59M 2026-03
Biogen USD 29.48B 43.6M 2026-03
BioMarin Pharmaceutical USD 8.59B 996.99M 2026-03
Bristol-Myers Squibb USD 86.48B 3.56B 2026-03
Coherus Biosciences USD 258.34M 258.18M 2025-12
Eisai JPY 1.45T 37.11B 2026-03
Eli Lilly USD 116.58B 4.1B 2026-03
Gilead Sciences USD 56.28B 2.74B 2026-03
GlaxoSmithKline GBP 62.87B 1.75B 2026-03
J&J USD 200.89B 1.68B 2026-03
Medtronic USD 91.48B 139M 2025-12
Merck USD 128.68B 8.18B 2026-03
Neurocrine Biosciences USD 4.91B 274.7M 2026-03
Novartis USD 118.53B 7.58B 2026-03
Pacira USD 1.21B 56.38M 2026-03
Perrigo USD 7.98B 551.9M 2026-03
Pfizer USD 207.62B 542M 2026-03
Regeneron Pharmaceuticals USD 40.87B 310.1M 2026-03
Roche Holding CHF 100.7B 5.94B 2025-12
Sanofi EUR 128.02B 1.22B 2026-03
UCB EUR 18.16B 971M 2025-12
Ultragenyx Pharmaceutical USD 1.3B 236M 2026-03
United Therapeutics USD 6.71B 1.17B 2026-03
Vertex Pharmaceuticals USD 26.48B 841.4M 2026-03
Zoetis USD 15.15B 313M 2026-03